Gabriela S. Hobbs, MD

Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.

Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.

In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.

Continuing their focus on optimizing JAK inhibitor therapy in myelofibrosis, panelists highlight dosing and adverse event management strategies.

A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.

A broader overview of the role that JAK inhibitors play in patients with myelofibrosis and how that role has continued to evolve in the current treatment paradigm.

Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy.

Expert panelists share brief insight on the current NCCN guidelines for selecting treatment in patients with myelofibrosis.

Focused discussion on the factors that help to select patients for stem cell transplantation over systemic therapy in the setting of myelofibrosis.

A comprehensive discussion on the respective role stem cell transplantation has in the treatment armamentarium for myelofibrosis.

Key opinion leaders in myelofibrosis management reflect on the role of biomarkers in informing treatment selection, even for patients with triple-negative disease.

Shared insight from a panel of experts on the current state of cytogenetics in myelofibrosis and how it impacts treatment pathways for patients.

Expert panelists provide an overview of the signs and symptoms indicative of myelofibrosis and consider factors that help to inform prognostication.